Anxiolytic Compounds Targeting GABAA Receptor Subunits
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anxiolytic drugs acting through the GABAA receptor's benzodiazepine site often cause sedation as a side effect, which is undesirable, and there is a need for compounds that interact more favorably with the α2 and/or α3 subunits to minimize sedation while maintaining anxiolytic activity.
Innovation Solution
Development of specific chemical compounds with improved solubility and metabolic stability that act as GABAA receptor agonists, preferentially interacting with the α2 and/or α3 subunits, thereby reducing sedative effects while maintaining anxiolytic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds act as GABAA receptor agonists at the benzodiazepine site, then anxiolytic activity is achieved, but sedation occurs as an undesirable side effect
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures that preferentially interact with the α2 and/or α3 subunits of the GABAA receptor rather than binding at the benzodiazepine site. This localized interaction approach allows the compound to exert anxiolytic effects through α2/α3 subunit activation while avoiding the sedative effects associated with benzodiazepine site binding. The chemical structure is specifically optimized to target this particular receptor subsite.
Solution Approach 2:
The patent employs parameter changes by modifying the pharmacological profile of GABAA receptor agonists through structural modifications. The compounds are designed with specific chemical parameters (molecular weight, functional groups, stereochemistry) that enable selective binding to α2/α3 subunits. This parameter optimization allows the receptor agonist to activate anxiety-related pathways while avoiding sedative pathways, thereby changing the overall pharmacological output profile.
2Reliability
If benzodiazepine-based anxiolytics are used, then anxiety disorders are treated effectively, but sedation and metabolic instability occur
Solution Approach 1:
The patent applies segmentation by dividing the GABAA receptor into its functional subunits (α1-6, β1-3, γ1-3, δ subunits) and targeting specifically the α2 and/or α3 subunits. This segmentation approach allows selective activation of anxiety-related receptor components while excluding sedative components associated with other subunits. The compound structure is designed to recognize and bind specifically to this segmented portion of the receptor.
Solution Approach 2:
The patent extracts the harmful sedative effect by removing the benzodiazepine binding site interaction from the pharmacological mechanism. Instead, the compound extracts and activates only the α2/α3 subunit pathway, leaving out the sedative α1 subunit activation and other benzodiazepine site interactions. This extraction approach isolates the desired anxiolytic effect from the unwanted sedative effect.
3Reliability
If compounds are designed for improved solubility and metabolic stability, then therapeutic efficacy is enhanced, but development complexity increases
Solution Approach 1:
The patent applies parameter changes systematically to optimize both therapeutic efficacy and pharmacokinetic properties. Molecular parameters such as lipophilicity, hydrogen bonding capacity, and molecular size are adjusted to improve solubility and metabolic stability. These parameter modifications are made in conjunction with the structural modifications needed for α2/α3 subunit selectivity, creating a multi-parameter optimization approach that balances efficacy and stability.
Solution Approach 2:
The patent employs composite molecular designs that combine multiple functional elements within a single compound structure. The molecules integrate pharmacophores for α2/α3 subunit binding with structural features that confer improved solubility and metabolic stability. This composite approach allows multiple desirable properties to be achieved simultaneously within a unified molecular architecture, reducing the need for separate optimization steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively treat anxiety disorders with reduced sedation, providing improved anxiolytic activity by targeting specific GABAA receptor subunits, thus offering a therapeutic advantage over existing benzodiazepine-based anxiolytics.
Implementation Method 1
The binding of GABA to specific receptors causes the opening of ion channels in the cell membrane which allows either the flow of negatively-charged chloride ions into the cell or positively-charged potassium ions out of the cell. This typically results in a negative change in the transmembrane potential which usually causes hyperpolarisation.
Data Source
AI summary
The present invention relates to chemical compounds of general formula (I)which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.